Torben Frøstrup Hansen (Torben F Hansen, Torben Schjødt Hansen)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 25

Top Topics

Systematic Review

Top Venues

Clinical case reports

International journal of cancer

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Sara Witting Christensen Wen, Morten Borg, Signe Timm, Torben Frøstrup Hansen, Ole Hilberg, Rikke Fredslund Andersen
Methylated Cell-Free Tumor DNA in Sputum as a Tool for Diagnosing Lung Cancer-A Systematic Review and Meta-Analysis. Cancers 16 (3) (2024)
Søren Rattenborg, Torben Frøstrup Hansen, Sören Möller, Erik Frostberg, Hans Bjarke Rahr
Non-Curative Treatment Choices in Colorectal Cancer: Predictors and Between-Hospital Variations in Denmark: A Population-Based Register Study. Cancers 16 (2) (2024)
Søren Rattenborg, Torben Frøstrup Hansen, Sören Möller, Erik Frostberg, Hans Bjarke Rahr
Non-Curative Treatment Choices in Colorectal Cancer: Predictors and Between-Hospital Variations in Denmark: A Population-Based Register Study. Cancers 16 (2) (2024)
Sara Witting Christensen Wen, Morten Borg, Signe Timm, Torben Frøstrup Hansen, Ole Hilberg, Rikke Fredslund Andersen
Methylated Cell-Free Tumor DNA in Sputum as a Tool for Diagnosing Lung Cancer-A Systematic Review and Meta-Analysis. Cancers 16 (3) (2024)
Louise Raunkilde, Torben Frøstrup Hansen, Birgitte Mayland Havelund, Caroline Emilie B Thomsen, Søren Rafael Rafaelsen, Jan Lindebjerg, Lars Henrik Jensen
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study. Acta oncologica (Stockholm, Sweden) (2023)
Carine El Sissy, Amos Kirilovsky, Christine Lagorce Pagès, Florence Marliot, Petra A Custers, Edina Dizdarevic, Marine Sroussi, Mireia Castillo-Martin, Nacilla Haicheur, Mohamed Dermani, Nicolas Loche, Bénedicte Buttard, Ana Maria Musina, Maria-Gabriela Aniței, José G van den Berg, Annegien Broeks, Soledad Iseas, Mariana Coraglio, Fernando Sanchez Loria, Alfredo Romero, Pierre Laurent-Puig, Aurélien de Reyniès, Laura M Fernandez, Karoui Medhi, David Tougeron, Carlos Alberto Vaccaro, Juan P Santino, Laurids Østergaard Poulsen, Jan Lindebjerg, Juan Manuel O'Connor, Viorel Scripcariu, Mihail-Gabriel Dimofte, Jean-Pierre Gerard, Myriam Chalabi, Nuno L Figueiredo, Rodrigo Oliva Perez, Angelita Habr-Gama, Jerome Galon, Torben Frøstrup Hansen, Lars Henrik Jensen, Geerard L O Beets, Guy Zeitoun, Franck Pagès
International Validation of the Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Morten Borg, Sara Witting Christensen Wen, Rikke Fredslund Andersen, Signe Timm, Torben Frøstrup Hansen, Ole Hilberg
Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis. Cancers 15 (15) (2023)
Liva K Stuhr, Kasper Madsen, Astrid Zedlitz Johansen, Inna Markovna Chen, Carsten Palnaes Hansen, Lars Henrik Jensen, Torben Frøstrup Hansen, Kirstine Kløve-Mogensen, Kaspar R Nielsen, Julia Sidenius Johansen
Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma. Cancers 15 (3) (2023)
Sara Witting Christensen Wen, Line Nederby, Rikke Fredslund Andersen, Torben Frøstrup Hansen, Christa Haugaard Nyhus, Ole Hilberg, Anders Jakobsen, Torben Frøstrup Hansen
NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. British journal of cancer (2023)
Liva K Stuhr, Kasper Madsen, Astrid Zedlitz Johansen, Inna Markovna Chen, Carsten Palnaes Hansen, Lars Henrik Jensen, Torben Frøstrup Hansen, Kirstine Kløve-Mogensen, Kaspar R Nielsen, Julia Sidenius Johansen
Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma. Cancers 15 (3) (2023)
Louise Raunkilde, Torben Frøstrup Hansen, Rikke Fredslund Andersen, Birgitte Mayland Havelund, Caroline Emilie B Thomsen, Lars Henrik Jensen
NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer. Cancers 14 (18) (2022)
Sara Witting Christensen Wen, Jan Wen, Torben Frøstrup Hansen, Anders Jakobsen, Ole Hilberg
Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer-A Systematic Review. Cancers 14 (9) (2022)
Edina Dizdarevic, Torben Frøstrup Hansen, Anders Jakobsen
The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal. Cancers 14 (9) (2022)
Søren Rafael Rafaelsen, Claus Dam, Chris Vagn-Hansen, Jakob Møller, Hans Bjarke Rahr, Mikkel Sjöström, Jan Lindebjerg, Torben Frøstrup Hansen, Malene Roland Vils Pedersen
CT and 3 Tesla MRI in the TN Staging of Colon Cancer: A Prospective, Blind Study. Current oncology (Toronto, Ont.) 29 (2) (2022)
Sara Witting Christensen Wen, Rikke Fredslund Andersen, Kristian Rasmussen, Caroline Emilie B Thomsen, Torben Frøstrup Hansen, Line Nederby, Henrik Hager, Anders Jakobsen, Ole Hilberg
Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer. Cancers 13 (16) (2021)
Robson Francisco Carvalho, Luisa Matos do Canto, Sarah Santiloni Cury, Torben Frøstrup Hansen, Lars Henrik Jensen, Sílvia Regina Rogatto
Drug Repositioning Based on the Reversal of Gene Expression Signatures Identifies TOP2A as a Therapeutic Target for Rectal Cancer. Cancers 13 (21) (2021)
Tonje Riise Hamre, Julie Kristine Stougaard, Birgitte Mayland Havelund, Lars Henrik Jensen, Torben Frøstrup Hansen
Re-exposure to immunotherapy in metastatic colon cancer: A case report. Clinical case reports 9 (6) (2021)
Kristian Blomberg, Torben Frøstrup Hansen, Claus Lohman Brasen, Jeppe B Madsen, Lars Henrik Jensen, Caroline Emilie B Thomsen
The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer. Cancers 13 (20) (2021)
Nadia Emad Lotfi Amin, Torben Frøstrup Hansen, Eva Fernebro, John Ploen, Jakob Eberhard, Jan Lindebjerg, Lars Henrik Jensen
Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations. International journal of cancer 149 (1) (2021)
Malene Roland Vils Pedersen, Søren Rafael Rafaelsen, Jan Lindebjerg, Torben Frøstrup Hansen, Hans Bjarke Rahr
The Impact of Patient Characteristics and Tumor Biology on the Accuracy of Preoperative Staging of Colon Cancer in Denmark. A Nationwide Cohort Study. Cancers 13 (17) (2021)
Torben Frøstrup Hansen, Camilla Qvortrup, Per Pfeiffer
Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers 13 (5) (2021)
Takatoshi Matsuyama, Raju Kandimalla, Toshiaki Ishikawa, Naoki Takahashi, Yasuhide Yamada, Masamichi Yasuno, Yusuke Kinugasa, Torben Frøstrup Hansen, Marwan Fakih, Hiroyuki Uetake, Balázs Győrffy, Ajay Goel
A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer. International journal of cancer 147 (11) (2020)
Sara Witting Christensen Wen, Rikke F Andersen, Lena Marie S Petersen, Henrik Hager, Ole Hilberg, Anders Jakobsen, Torben Frøstrup Hansen
Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma. Cancers 12 (12) (2020)
Natacha Dencker Trabjerg, Christina Rask, Lars Henrik Jensen, Torben Frøstrup Hansen
Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report. Clinical case reports 7 (7) (2019)
Lars Henrik Jensen, René Olesen, Lone Noergaard Petersen, Anders Kindberg Boysen, Rikke Fredslund Andersen, Jan Lindebjerg, Lise Nottelmann, Caroline Emilie Brenner Thomsen, Birgitte Mayland Havelund, Anders Jakobsen, Torben Frøstrup Hansen
NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer. Cancers 11 (11) (2019)